Cancer

Title
A Randomized Trial Using Pimasertib or Dacarbazine in Patients with N-Ras Mutated Locally Advanced Metastatic Melanoma
Trial Number
204937121912
Number of Participants
184
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

Patients must be 18 years of age or older and have the following:
measurable, histologically or cytologically confirmed, unresectable locally advanced or metastatic cutaneous melanoma (stage III c or M1a-c) N-Ras mutated. (If N-Ras mutational status is unknown at screening, it must be prospectively defined before inclusion. If N-Ras mutational status is already known before screening, it must be retrospectively confirmed after inclusion by the sponsor.); tumor lesions amenable to biopsy or available tumor tissue as archival samples; women of childbearing potential must have a negative blood pregnancy test at the screening visit .

Purpose

To compare the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.